Dosing Enhancements May Improve Treatment Experience for Patients Receiving AVONEX® (interferon beta-1a) for Multiple Sclerosis WESTON, Mass.--(BUSINESS WIRE)--Today Biogen Idec (NASDAQ: BIIB) ...

European Commission approves the first single-use intramuscular autoinjector designed to improve convenience of once-weekly AVONEX (interferon beta-1a) administration “At Biogen Idec, our commitment ...

-- First single-use intramuscular autoinjector designed to improve convenience of once-weekly AVONEX recommended for approval in the European Union and authorised in Canada -- AVONEX PEN is designed ...

Biogen Idec says that, following the withdrawal of its multiple sclerosis drug, Tysabri (natalizumab), after it was linked to two cases of the rare central nervous system disease, progressive ...

Biogen Idec’s multiple sclerosis drug Avonex can cause severe liver damage, U.S. regulatory officials and the company warned Wednesday, the latest in a series of blows to MS patients. “In some cases, ...

WESTON, Mass. — The Food and Drug Administration has approved two separate dosing innovations for multiple sclerosis patients that are being treated with a Biogen Idec drug. Biogen Idec said the FDA ...

ZUG, Switzerland--(BUSINESS WIRE)--Third paragraph, first sentence should read: ....AVONEX 30mcg/0.5ml... (sted ...AVONEX 30mcg/50ml...) The corrected release reads ...